Observations from ID and Beyond: Mayo Clinic Study on Paxlovid Outcomes Is Reassuring — But Likely Underestimates Rebound Rate

Mayo Clinic researchers recently published a retrospective analysis of nirmatrelvir/ritonavir (Paxlovid) treatment for COVID-19. The data on the rate of severe outcomes is reassuring, says Dr. Paul Sax in the latest HIV and ID Observations post, but it likely underestimates the rebound rate. Additionally, questions remain about whether treatment with subsequent rebound reduces — or increases — the time people are contagious,

Do you want to be notified whenever Dr. Sax posts? Sign up to receive notifications by email by using the Subscribe box.

Want to see more from NEJM Journal Watch? Register here.